Available online on 15 Sep, 2025 at https://ijdra.com/index.php/journal

International Journal of Drug Regulatory Affairs

Published by Diva Enterprises Pvt. Ltd., New Delhi
Associated with Delhi Pharmaceutical Sciences & Research University

Review Article **Open Access**

Drug Labelling Regulations in the USA, Europe, and India: An Overview

Pradnya L. Shinde*, Kranti L. Satpute, Rohit R. Sarda, Sagar S. Gilda, Nirbhay B. Chalmale

Regulatory Affairs Department, Dayanand Education society's Dayanand College of Pharmacy, Latur, India.

Abstract

Labelling on drugs is a vital communication means that facilitates proper use of medicine safely and effectively by communicating core information to prescribing physicians and patients. *Objective*: This research aims to provide comparative examination of requirements for prescription labelling in three regulatory super jurisdictions: The United States of America, the European Union, and India. *Data source*: The research comprehensively analyses the regulatory directives for labelling exercises in these regulatory super jurisdictions, which include the guidelines of the U.S. FDA, the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organization (CDSCO).

***Conclusion*:** Regulatory expectations regarding key components such as labelling formats, required content, language, and patient safety and risk communication strategies are found to be majorly similar and divergent. This study identified regulatory gaps, industry challenges, and potential harmonization strategies to facilitate global trade. By understanding these frameworks, stakeholders can navigate compliance more efficiently, fostering growth in labelling practices across the USA, Europe, and India.

Keywords: Drug Labelling; Label; Package insert; SmPC; US-FDA; CDSCO; EMA

Article Info: Received 19 Aug 2025; Review Completed 11 Sep 2025; Accepted 14 Sep 2025

Cite this article as:
Shinde PL, Satpute KL, Sarda RR, Gilda SS, Chalmale NB. Drug Labelling Regulations in the USA, Europe, and India: An Overview. Int. J. Drug Reg. Affairs [Internet]. 2025 Sep 15 [cited 2025 Sep 15]; 13(3):95-102. Available from: http://ijdra.com/index.php/journal/article/view/796

DOI: 10.22270/ijdra.v13i3.796
*Corresponding author. E-mail address: pradnyashinde951@gmail.com (P L Shinde)

1. Introduction

A label is any written, printed, or visual material that is displayed on the immediate container of an article, or that is attached to a consumer good or that is attached to or visible on a package that contains a consumer good. (1) A drug label is any printed information that comes with a prescription medication, over-the-counter medication, or nutritional supplement. The written, printed, or visual information that is shown on medications or their containers, along with the items that go with them, is referred to as pharmaceutical labelling, sometimes called drug labelling or prescription labelling. Identification of the medicine's components and the provision of precise instructions and warnings about its administration, storage, and disposal are the main goals of drug labelling. Drug labels help patients properly utilize their medications by identifying their components and providing advice. Additionally, it helps medical professionals prescribe and administer drugs. Drug labelling regulations vary by nation and area and are impacted by healthcare systems, recent events, and business objectives. (2)

1.1 Prescription Drug and Their Importance

Drug labels are used to identify the composition of drugs, provide instructions, and help patients take their medications as prescribed. The main goal of pharmaceutical labelling is to clearly and unambiguously identify the medication and the requirements for its safe use. (3) Prescription medications treat, manage, and prevent a variety of medical disorders, making them essential to modern healthcare. Due to their strength, propensity for adverse effects, and potential for abuse, prescription pharmaceuticals, in contrast to over-the-counter ones, require a valid authorization from a licensed healthcare professional. (4) Prescription medication labels are an essential means of interaction with patients, pharmacists, and healthcare professionals. Despite their significance, a large body of studies finds that people frequently misinterpret label instructions, which can result in prescription mistakes and worse health outcomes. Pharmaceutical medications are essential to medical care, yet not all of them are freely accessible to the general people. Because of their intricacy and possible hazards, prescription medications are unique in that they must be supervised by a doctor. In order to ensure that these medications are utilized appropriately for diagnosed diseases, they must be prescribed by licensed doctors. Prescription drugs are becoming more and more complex, which emphasizes the importance of comprehending their appropriate function in healthcare. (5)

Prescription medications must be supervised by a physician. However, the label takes over as the primary means of communication as soon as they are given to the patient. The label fills in the gaps between what the patient

understands, what the pharmacist knows, and what the doctor intended. Particularly for those with low health literacy, prescription medicine labels are essential for reducing the risks of nonadherence, overuse, dependency, and public confusion. To ensure safe drug practices, particularly for vulnerable groups, prescription labels are essential and serve as more than just administrative tools. Labelling that is accurate, patient-friendly, and clear can significantly lower the risk of drug-related harm and enhance health outcomes. (6)

1.2 Types of labels

Manufacturer Label - A manufacturer label is one that is provided by the manufacturer, packer, or distributor that includes information on the medication for use by physicians, pharmacists, or nurses. The minimal information that must be included on the label of any medication is mandated by Rule 96 of the Drug and Cosmetic Rules (Manner of Labelling).

Dispensing label - Labels for delivered medications are crucial for informing customers about medications and guaranteeing proper medication use. The important information required for the consumer to use their medications safely and efficiently must be included on the label of the medication that is being supplied. It is legally mandatory that all medications be labelled before being given to the patient. The information about the medication in a prescription is used to generate labels. When the medication is being dispensed, the label is placed on the packaging.

2. Drug labeling requirements in India

In India, drug labelling is governed by the Central Drugs Standard Control Organization (CDSCO). In India, the Ministry of Health and Family Welfare oversees the CDSCO, which are responsible for regulating pharmaceuticals and cosmetics. The legal framework for drug labelling in India is established by the Drugs and Cosmetics Act, 1940, and its ensuing revisions. Guidelines for labelling formats and content are published by the CDSCO. The Drugs and Cosmetics (Labels) Rules, 1970 are among the recommendations published by the CDSCO that specify labelling criteria for several drug categories. (7)

2.1 Key Documents for Package Insert Labelling Regulations:

The "Drugs and Cosmetics Act (1940) and Rules (1945)" govern the development of package insert rules in India. Schedule D contains eight parameters related to therapeutic indications in section 6.2 and eight parameters related to pharmacological information in section 6.3. The package insert must be in "English," under Section 6.2. Guidelines for labelling the content and format of the innermost and outermost medicine containers are provided by Rules 96 and 97.

3. Drug labeling requirements in the USA

In the United States, the main regulatory agency in charge of medicine labelling is the Food and medicine Administration (FDA). The FDA is authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act) to create labelling guidelines for both prescription and over the counter (OTC) medications. Through its Center for Drug Evaluation and Research (CDER), the FDA upholds these rules. A few guidance documents that offer comprehensive directions on labelling format and content are published by the CDER. Comparable to CDSCO, the US Food and Drug Administration (US FDA) are responsible for regulating and overseeing the safety of food, medications, vaccines, nutritional supplements, biological medical goods, blood products, medical devices, and cosmetics. It has four directorates that supervise the agency's operations in addition to the Office of Commissioner.

The Food and Drug Administration (FDA) is revising its rules for the format and content of labels for prescription drugs for humans, including biological products that fall within the drug category. To update its rules governing the structure and content of labelling for human prescription medication products, which are found in 21 CFR 201.56 and 201.57 (21 CFR 201.56 and 201.57), the FDA released a proposed rule. According to the final regulation, all FDA-approved patient labelling for both new and recently approved products as well as older products must be reprinted with or included with the labelling. Additionally, the final rule clarifies some criteria in the present regulations for prescription medicine labelling of older goods. With these modifications, medical professionals will be able to learn more from the labelling of older products. (8)

Guidelines for the format and content of labels for biological products and prescription medications for humans

Labelling for prescription drugs as outlined in § 201.100(d) must adhere to the following general standards:

- The label must include an overview of the key scientific data required for the medication's safe and efficient usage.
- The labelling must be factual and educational, without any false or misleading information or a commercial tone. The labelling must be revised whenever new information becomes available that makes the labelling incorrect, misleading, or inaccurate in line with this chapter's §§ 314.70 and 601.12.
- Labelling must, if feasible, be grounded in information gleaned from human experience. If there is not enough proof of safety or significant proof of efficacy, no inferred claims or recommendations of drug use may be made.

Prescription medication categories that must adhere to the format and content criteria for labels specified in §§ 201.56(d) and 201.57

- Pharmaceutical items for which the Food and Drug Administration (FDA) approved an efficacy supplement, biologics licensing application (BLA), or new drug application (NDA) between June 30, 2001, and June 30, 2006;
- Prescription medication products for which an efficacy supplement, BLA, or NDA was not yet submitted on June 30, 2006; or prescription

medication products for which an efficacy supplement, BLA, or NDA was submitted at any point on or after June 30, 2006.

Implementation schedule for §§ 201.56(d) and 201.57's labelling content and format requirements

- Proposed conforming labelling must be included in the application for drugs for which an NDA, BLA, or efficacy supplement is filed for approval on or after June 30, 2006.
- A supplement with suggested conforming labelling must be submitted by June 30, 2009, at the latest, for drugs for which an NDA, BLA, or efficacy supplement is pending as of June 30, 2006, or that have been approved at any point between June 30, 2005, and June 30, 2006.
- Products for which an efficacy supplement, BLA, or NDA was approved between June 30, 2004, and June 29, 2005, must submit a supplement with suggested conforming labelling by June 30, 2010.
- At the latest, on June 30, 2011, a supplement with suggested conforming labelling must be filed for products for which an NDA, BLA, or efficacy supplement has been approved at any point between June 30, 2003, and June 29, 2004.
- Products for which an efficacy supplement, BLA, or NDA was approved between June 30, 2002, and June 29, 2003, shall submit a supplement with suggested conforming labelling by June 30, 2012.

3.1 Labeling requirements for new and more recently approved prescription drug products

Labelling for prescription drugs as outlined in § 201.100(d) must include the exact information mandated by § 201.57(a), (b), and (c) under the following headings and subheadings, and in the following order:

1. Highlights of Prescribing Information
    a) Product Names, Other Required Information
    b) Boxed Warning
    c) Recent Major Changes
    d) Indications and Usage
    e) Dosage and Administration
    f) Dosage Forms and Strengths
    g) Contraindications
    h) Warnings and Precautions
    i) Adverse Reactions
    j) Drug Interactions
    k) Use in Specific Populations
2. Full Prescribing Information: Contents
3. Full Prescribing Information
   Boxed Warning
    a) Indications and Usage
    b) Dosage and Administration
    c) Dosage Forms and Strengths
    d) Contraindications
    e) Warnings and Precautions
    f) Adverse Reactions
    g) Drug Interactions
    h) Use in Specific Populations
        - Pregnancy
        - Lactation
        - Females and Males of Reproductive Potential
        - Pediatric use
        - Geriatric use
4. Drug Abuse and Dependence
    a. Controlled substance
    b. Abuse
    c. Dependence
    d. Over dosage
5. Description
6. Clinical Pharmacology
    i. Mechanism of action
    ii. Pharmacodynamics
    iii. Pharmacokinetics
7. Nonclinical Toxicology
8. Carcinogenesis, mutagenesis, impairment of fertility
9. Animal toxicology and/or pharmacology
10. Clinical Studies
11. References
12. How Supplied/Storage and Handling
13. Patient Counseling Information

3.2 Key documents for package insert Labelling regulations

The same rules apply in the United States under Title 201, Parts 201, 314, and 601 of the Code of Federal Regulations (21 CFR points 201, 314, 601). The General and Permanent Rules that are published in the Federal Register by the Federal Government's Executive departments and agencies are codified in CFR. The CFR's Title 21 is set aside for Food and Drug Administration regulations. A Patient Package Insert (PPI), sometimes known as a package insert, is a document that informs medical practitioners about how to prescribe a medication in the United States. It is made by the pharmaceutical company and authorized by the US Food and Drug Administration. The insert, which comes with the medication package, is used to make labelling and promotional materials.

Healthcare professionals, such as physicians, nurse practitioners, physician assistants, pharmacists, and nurses, are the target audience for the prescribing information. An overview of the key scientific data required for the medication's safe and efficient usage can be found in the prescribing information. (9)

4. Drug labeling requirements in Europe

CHMP, an agency of the European Medicine Agency (EMA), is responsible of human medication labelling in Europe. In accordance with EU laws, there are several mandatory prerequisites. This includes the product function, batch number, nation, nominal content, DOMD and PAO dates, particular usage warnings and precautions, and the name and address of the person in charge. CE is the most widely recognized European conformity mark. Products provided within the European Economic Area are certified to meet health, safety, and end-environmental protection standards by the CE mark. According to Articles 54, 55, and 59 of Directive 2001/83/EC of the European Parliament, medical items for human use must be accompanied by outward and/or immediate packaging

information (labelling) and a package leaflet. A package leaflet is not necessary when all the necessary information is displayed on the box, according to Article 58 of Directive 2001/83/EC. The main source of rules governing medicine labelling requirements in the European Union is Directive 2001/83/EC. Directive 2001/83/EC's Title V contains a list of all the requirements and elements. The Community code pertaining to human-use pharmaceuticals is established by this directive, which also contains comprehensive guidelines for pharmaceutical labelling and packaging. (10)

4.1 Summary Product Characteristics (SmPCs)

Based on their product research and expertise, pharmaceutical companies create and update monographs for medications called Summary of Product Characteristics, or SmPC. Form, clinical characteristics, and pharmacological qualities are among the crucial details concerning medications that are outlined. SmPCs are the cornerstone of training medical professionals on how to use medications safely and effectively, and they are necessary for the marketing authorization of all EU-approved drugs. Over the course of a medication's life, they are updated if new safety or efficacy data becomes available. SmPCs are essential papers for helping patients receive pharmaceutical information because they provide the basis for package leaflets. (11)

4.2 Key documents for SmPCs Labelling regulations

To comply with the Labelling requirements for medicinal products, the European Union's (EU) regulatory system for pharmaceutical products heavily relies on the Summary Product Characteristics (SmPCs). Here is an overview of the key roles of SPCs in the context of EU Labelling requirements:

1. Name of medicinal product
2. Qualitative and quantitative composition
3. Pharmaceutical form
4. Clinical Particulars:
    a) Therapeutic indications
    b) Posology and method of administration
    c) Contraindications
    d) Special warnings and precautions for use
    e) Interaction with other medicinal products and other forms of interaction
    f) Fertility, pregnancy and lactation
    g) Effects on the ability to drive and use machines
    h) Undesirable effects
    i) Overdose
    j) Pharmacological Properties
    k) Pharmacodynamic properties
    l) Pharmacokinetic properties
    m) Preclinical safety data
5. Pharmaceutical particulars
    a) List of excipients
    b) Incompatibilities
    c) Shelf life
    d) Special precautions for storage
    e) Nature and contents of container
    f) Special Precaution for Cisposal and Other Handling of the product

5. Impact on patient safety

Drug labels give consumers and healthcare professionals vital information, which is why they are so important for patient safety. Treatment outcomes, medication errors, adverse drug reactions (ADRs), and general patient safety can all be greatly impacted by the completeness, correctness, and clarity of prescription labels. Patient safety is the top priority in the healthcare industry, and one of the most important aspects of that safety is making sure that medications are provided correctly. Because it provides patients and healthcare professionals with vital information, drug labelling is a vital tool in ensuring safe pharmaceutical usage. It contains details about possible side effects, dosing guidelines, contraindications, and appropriate storage conditions—all of which are crucial for avoiding mistakes and guaranteeing the right therapeutic result. Medication errors and adverse drug reactions (ADRs) are still a major source of harm in healthcare systems around the world, despite the crucial role that drug labelling plays. (12)

Drug labels must be accurate, consistent, and unambiguous in order to reduce medication errors, according to regulatory guidelines from organizations like the FDA (USA), EMA (Europe), and CDSCO (India). Labels in areas with strict regulations, like the USA and Europe, contain important information such as active components, dose guidelines, contraindications, and black box warnings. By assisting patients with proper medication use, these reduce the possibility of dangerous drug interactions or overdosing.

Furthermore, a variety of individuals with different literacy levels, languages, and cultural backgrounds frequently take drugs in the age of globalization. Because they can increase patient comprehension and lower the chance of prescription errors, multilingual and culturally sensitive medicine labels are becoming more and more necessary.

a) Accuracy in Dosage and Administration

Proper prescription of pharmaceuticals by healthcare experts is made possible by clear and accurate instructions on dosage, frequency, and administration routes. Additionally, patients depend on this information to make sure they take the right dosage at the right time. The right dosage is prescribed and given when labels are properly labelled. Underdosing may occur due to inaccurate labeling, including vague dosing instructions or incorrect units of measurement

b) Indications and Contraindications

Along with any conditions or patient groups for which a medication may not be appropriate, labelling offers information regarding a drug's approved uses. In addition to ensuring that drugs are prescribed within their intended scope, this helps reduce unpleasant effects.

c) Side Effects and Warnings

A list of possible adverse effects, together with information on their frequency and severity, is part of comprehensive labelling. Patients and medical staff are

better equipped to identify and handle any side effects that may occur during treatment thanks to this knowledge.

d) Storage and Handling

In order to preserve the stability and effectiveness of pharmaceuticals, proper storage recommendations are essential. Labels frequently include instructions for handling, temperature, light exposure, and other storage conditions that help avoid contamination or deterioration. (13)

e) Prevention of Wrong Drug Administration

Labels are crucial identifiers that help avoid giving the patient the incorrect medication. This is especially crucial in pharmacies or hospitals that handle a lot of prescription drugs. A medicine mix-up with disastrous results might be caused by a single digit miscalculation or unclear prescription names.

Table 1. Impact of Drug Labels on Patients Safety

Impact Area	With Strong Regulatory Standards (USA/EU)	With Weaker Enforcement (India)
Patient Safety	High, due to detailed and structured information	Compromised by vague or incomplete labeling
Risk Awareness	Enhanced through boxed warnings and PILs	Limited, especially in low-literacy settings
Medication Adherence	Improved by clear instructions	Lower due to misunderstanding or confusion
Self-Medication Control	Controlled via prescription-only labeling	Common due to poorly enforced label requirements
Comprehension by Public	Tested and optimized for readability	Often technical or poorly translated

5.1 Impact of Drug Labels on Patients Safety

The effectiveness of a drug label in promoting safe medicine usage is directly influenced by regulatory criteria. Better patient outcomes are intimately linked to stronger standards, as in the USA and Europe, whereas adverse drug events and usage are more likely in areas of India where laws are weak or inconsistently enforced. Drug labelling has a major effect on patient safety, adherence, and general health outcomes. Better patient comprehension, fewer medication errors, and increased adherence to treatment regimens are the outcomes of regulatory standards that demand labels that are accessible, organized, and unambiguous, like those imposed by the FDA and EMA. Conversely, less stringent enforcement of regulations, as observed in certain regions of India, leads to misunderstandings, abuse, and an increased likelihood of unfavourable consequences. To maximize the efficacy of healthcare systems around the world and improve patient safety, drug labelling processes must be improved and standardized globally.

6. Technological and future trends in drug labels

Drug labeling plays a critical role in ensuring the safe and effective use of medications. As technology advances and globalization increases, drug labeling has evolved to incorporate modern tools and strategies. Artificial intelligence integration is one of the new technologies in digital labelling, as is the possibility of worldwide harmonization to solve present issues and enhance medication efficiency, safety, and accessibility. Advances in digital technologies, artificial intelligence (AI), and international harmonization initiatives are driving a major change in drug labelling in the pharmaceutical sector. Digital tools, artificial intelligence, and standardized standards are among the technological developments in drug labelling that are poised to transform the pharmaceutical sector. Adopting these trends promises to enhance patient safety, regulatory compliance, and worldwide accessibility, forming a more integrated and effective healthcare ecosystem, even though obstacles still exist. Here is a thorough analysis of these new patterns backed up by pertinent references.

a) Digital Labelling

By utilizing modern technology to improve accessibility, convenience, and engagement, digital labelling is revolutionizing the way that drug information is conveyed to patients and healthcare professionals. The use of modern digital techniques to improve the usability and accessibility of drug information is referred to as digital labelling. (14) The following subsections highlight key advancements.

b) QR Codes

Drug packaging is increasingly including QR codes, which direct consumers to dynamic content like product brochures, dosage calculators, and instructional videos. This method lessens the need for printed documents and guarantees real-time updates. Pharmaceutical packaging that incorporates QR codes enables consumers to scan the code with a smartphone to receive comprehensive medication information, instructional videos, and dose instructions. This method improves adherence and safety by guaranteeing that patients receive complete and current information. (15) QR codes provide a bridge between physical drug labels and dynamic digital content. By scanning a QR code, users can access: Patient-specific medication guides, instructional videos for proper administration, updated safety warnings and regulatory information.

c) Digital Health Apps

Patients can receive individualized pharmaceutical advice, reminders, and safety alerts through companion apps. Personalized medication management features, such as adherence monitoring, reminders, and direct lines of communication with medical professionals, are offered by companion apps. These applications can provide patients

with individualized support by integrating with electronic health records. (16) Digital health apps associated with medications offer personalized patient support, including medication adherence reminders, side effect monitoring and reporting, integration with wearable devices to track health metrics and ensure compliance.

d) Smart Labelling

To maintain the quality of the medication across its entire lifecycle, smart labels use sensors or digital components that monitor variables like temperature and humidity. In order to accept, execute, and ensure compliance with technical improvements in smart labelling, the regulatory affairs (RA) department is essential. Regulatory affairs specialists make ensuring these advancements comply with safety, quality, and legal requirements as the pharmaceutical sector moves toward digital and intelligent labelling solutions. Smart labels can improve supply chain transparency and patient safety by monitoring environmental conditions, authenticating products, and giving stakeholders access to real-time data. (17) Smart labels incorporate advanced technologies such as NFC (Near Field Communication), temperature and humidity sensors, track-and-trace systems.

7. Globalization and Future Harmonization

The pharmaceutical industry operates in a highly regulated environment with stringent labelling laws and information exchange requirements. Pharmaceutical firms have to handle the labelling of several product variations to meet the diverse needs of patients and medical experts. The pharmaceutical industry's globalization emphasizes the necessity of regionally uniform drug labelling procedures to enhance medication safety, lower errors, and expedite regulatory approvals. (18)

To ensure consistent and effective labelling, it is essential to standardize key elements such as medication names, dosage forms, strengths, and indications by using a uniform label template that includes these critical components. Leveraging technology through centralized labelling software can streamline content management, enhance version control, and reduce errors during creation, review, and approval processes. Cross-functional collaboration among Regulatory Affairs, Marketing, Quality Control, and Packaging teams is vital to harmonize labelling strategies and maintain accurate product information. Simplifying and consolidating information with clear graphics, standardized icons, and concise language helps improve readability and prevent information overload for patients and healthcare professionals, while prioritizing safety and essential instructions. Finally, conducting user testing and gathering feedback from patients, healthcare providers, and user experience experts enables continuous improvement through iterative design, ensuring the labels are both effective and user-friendly.

8. Result and Discussion

A comparative analysis of prescription drug labelling in the United States, Europe, and India reveals significant differences in regulatory frameworks, enforcement, language requirements, and patient information standards. The U.S. and EU maintain robust, standardized, and patient-centric labelling systems enforced by the FDA and EMA, respectively, ensuring clear, consistent, and accessible drug information. They mandate comprehensive patient leaflets, structured content formats, traceability systems, and detailed warnings. In contrast, India, regulated by the CDSCO, shows greater variability in label structure, less uniform enforcement, and limited requirements for patient information, especially outside high-risk drugs. While India's system includes essential elements, modernization and alignment with global best practices are needed to improve safety, comprehension, and public health outcomes.

Table 2. Differences in the Requirements of Prescription Drug Labelling in USA, Europe and India

Parameters	USA	Europe	India
Regulatory Authority	Food and Drug Administration (FDA)	European Medicines Agency (EMA) & National Agencies	Central Drugs Standard Control Organization (CDSCO)
Regulatory Framework	Governed by the Federal Food, Drug, and Cosmetic Act (FDCA)	Governed by EU Regulations, e.g., EC No 726/2004 for Central Marketing	Governed by the Drugs and Cosmetics Act, 1940
Language	English (can include bilingual for some regions)	Local language(s) of the member state are required	English (with regional language optional)
Prescription Symbol	"Rx only"	**"POM"** (Prescription Only Medicine)	"Rx only"
Size of Label	Generally standardized, with variations for different drug type	Similar to the USA in size due to detailed information and multilingual requirements	May vary in size and format
Patient Information Leaflet (PIL)	Required for **most** prescription drugs, especially those with significant side effects or complex instructions	Required for all prescription drugs	Required for **certain** drugs, mainly high-risk ones
Order of Label display	Highlights of Prescribing Information include all the parameters that involve	It includes address and name of the manufacturer. Also includes lot number, batch	Section 6.2: Therapeutic Indications Section 6.3:

	pharmacokinetics and pharmacodynamics of the drug	number, indication, storage and handling.	Pharmaceutical Information
Code No.	NDC (National Drug Code) number	UPC (Universal product code) number	Barcode number
Package Insert Format	PLR format	PLR format	Not specific format
Warnings & Precautions	A summary of the most clinically significant information is needed with any appropriate subheadings	Common, serious side effects, with **long-term effects**	Box warning is required if drug come under schedule (H,G,X)
Expiry Date Format	Month/Year or Day/Month/Year (MM/YYYY or DD/MM/YYYY) Expiry date may include the **day**, especially for high-risk drugs, ensuring clarity.	Day/Month/Year (DD/MM/YYYY) The expiry date often includes the **specific day,** with the last day of the specified month.	Month/Year (MM/YYYY) The expiry date is generally shown as **Month/Year** with the **last day of the month** assumed.
Adverse reaction	It should be included but not repeated if it is already in warning and precaution section	It should be included in the label (ADRs are included under **"Adverse Reactions"**, but if a reaction is severe or serious, it may be mentioned again in the **"Warnings and Precautions"** section to ensure that healthcare providers are aware of the risk)	May not always be repeated in **Warnings and Precautions.** Less comprehensive labeling, focus on common ADRs
Schedule	Drug come under schedule (H, G, X, etc)	NA	Drug come under schedule (H, G, X, etc)
Pregnancy and Lactation Warnings	Must include information on risks to pregnancy and lactation (if applicable)	Similar to USA, with category and risk information	Must include similar warnings, but the specific format may differ

9. Conclusion

This comparative analysis brings to light the central importance of regulatory structures in determining prescription drug labelling throughout the United States, Europe, and India. Each region utilizes a unique methodology, based on its legal frameworks, healthcare infrastructures, language diversity, and public health needs. In spite of these divergences, all three regions seek to make drug labelling contribute to safe, effective, and informed use of medicines by physicians and patients.

The similarities and differences in prescription drug labelling requirements across the United States, the European Union, and India highlight distinct regulatory priorities shaped by each region's legal frameworks, healthcare systems, and administrative capabilities. In the United States, the Food and Drug Administration (FDA) has established a very structured, electronically retrievable labelling system that focuses on clarity, completeness, and consistency in the Structured Product Labelling (SPL) format. The system allows for electronic integration and clinical decision-making support through updated and standardized information.

Conversely, the European Union—headed by the European Medicines Agency (EMA)—has a more decentralized but harmonized strategy. The EU emphasizes multilingual labelling obligations, patient information leaflets, and cross-border availability, considering the linguistic and cultural heterogeneity between member states. Risk minimization and pharmacovigilance aspects are deeply embedded in EU labelling policies.

India, governed by the Central Drugs Standard Control Organization (CDSCO), is updating its drug labelling regulations to conform more closely to global standards. Although traditionally less comprehensive, Indian regulations are being reformed to enhance transparency, enhance regulatory control, and include key components such as patient education, digital integration, and pharmacovigilance.

The comparative analysis identifies several important divergences: the degree of detail needed, the form of information delivery (electronic versus physical), language factors, and the degree of patient involvement. These divergences can present challenges to international pharmaceutical companies in ensuring compliance across jurisdictions, but they also provide opportunities for regulatory convergence and best-practice exchange.

Harmonization of essential labelling components—e.g., drug safety alerts, standardized headings, dosage directions, and contraindications—would greatly contribute to public health by minimizing errors, enhancing patient compliance, and facilitating cross-border pharmaceutical trade. Yet harmonization needs to be weighed against the necessity for local adaptation, particularly in linguistically complex and resource-poor environments.

Finally, this research recommends a collaborative international discussion between regulatory agencies to determine best practices and create common but flexible labelling frameworks. By doing so, the worldwide level of drug information would be raised, health disparities would be lessened, and patients everywhere would receive safe and effective treatment based on clear, consistent, and understandable labelling.

Acknowledgements

We would like to express our gratitude to the management of Dayanand Education Society Latur for supporting our work at Dayanand College of Pharmacy Latur.

Financial Disclosure statement:

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Reference

1. U.S. Food and Drug Administration. 21 CFR (Code of Federal Regulations), Part 201, Subpart C [Internet]. Silver Spring (MD): USFDA; [cited 2025 Jan 4]. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-C
2. Wikipedia contributors. Drug labelling [Internet]. Wikipedia; [cited 2025 Jan 25]. Available from: https://en.wikipedia.org/wiki/Drug_labelling
3. Medicines and Healthcare products Regulatory Agency. Best practice guidance on the labelling and packaging of medicines [Internet]. London: MHRA; 2015 Nov [cited 2025 Jan 25]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/474366/Best_practice_guidance_Labeling_and_packaging_of_medicines.pdf
4. Shrank WH, Agnew-Blais J, Choudhry NK, Wolf MS, Orav EJ, Avorn J, et al. A patient-centered prescription drug label to promote appropriate medication use and adherence [Internet]. Arch Intern Med. 2007 [cited 2025 Aug 16];167(16):1648–55. Available from: https://www.researchgate.net/publication/306329118_A_Patient-Centered_Prescription_Drug_Label_to_Promote_Appropriate_Medication_Use_and_Adherence
5. Shrank WH, Avorn J, Rolon C, Shekelle P. Effect of content and format of prescription drug labels on readability, understanding, and medication use: a systematic review. Ann Pharmacother. 2007;41(5):783–801. Available from: https://www.researchgate.net/publication/51390229_Effect_of_Content_and_Format_of_Prescription_Drug_Labels_on_Readability_Understanding_and_Medication_Use_A_Systematic_Review
6. Wolf MS, Davis TC, Shrank W, Neuberger M, Parker RM. To err is human: patient misinterpretations of prescription drug label instructions. Patient Educ Couns. 2007;67(3):293–300. Available from: https://pubmed.ncbi.nlm.nih.gov/17587533/
7. Makvana SH, Deshpande S, Zaveri M. Comparative analysis of drug labeling requirements in the USA and India: regulatory frameworks and compliance standards. Int J Pharm Sci. 2024;2(6):701–7. Available from: https://www.ijpsjournal.com/article/Comparative+Analysis+Of++Drug+Labeling++Requirements+In+The+USA+And+India+Regulatory+Frameworks+And+Compliance+Standards
8. U.S. Food and Drug Administration. Requirements on content and format of labeling for human prescription drug and biological products [Internet]. Fed Regist. 2006 Jan 24 [cited 2025 Feb 02];71(15):3922–97. Available from: https://www.federalregister.gov/documents/2006/01/24/06-545/requirements-on-content-and-format-of-labeling-for-human-prescription-drug-and-biological-products
9. Global Research Online [Internet]. [cited 2025 Mar 14]. Available from: https://globalresearchonline.net/journalcontents/v67-2/10.pdf
10. Webretailer. EU product regulations [Internet]. [cited 2025 Apr 17]. Available from: http://www.webretailer.com/lean-commerce/eu-product-regulations/
11. Royal Pharmaceutical Society. Summary of product characteristics [Internet]. [cited 2025 Mar 23]. Available from: https://www.rpharms.com/development/trainee-pharmacists/product-characteristics-summary
12. U.S. Food and Drug Administration. Labeling for human prescription drug and biological products – implementing the PLR content and format requirements. Silver Spring (MD): FDA; [cited 2013 Feb 23] Available from: https://www.fda.gov/files/drugs/published/Labeling-for-Human-Prescription-Drug-and-Biological-Products---Implementing-the-PLR-Content-and-Format-Requirements.pdf
13. Parate N. Labeling and pharmacovigilance: safeguarding safety and accuracy [Internet]. Freyr Solutions. 2023;14(2):67–9 [cited 2025 Sep 14]. Available from: https://www.freyrsolutions.com/blog/labeling-and-pharmacovigilance-safeguarding-safety-and-accuracy
14. Baird M. The future of labels: embracing digital technology for enhanced efficiency. Schlafender Hase. [cited 2025 Mar 3];68(4):89–92. Available from: https://www.schlafenderhase.com/shblog/the-future-of-labels-embracing-digital-technology-for-enhanced-efficiency
15. Freyr Solutions. Enhancing patient safety: the role of QR code implementation in pharma labeling [Internet]. 2024 [cited 2025 Sep 14];24(6):152–5. Available from: https://www.freyrsolutions.com/blog/enhancing-patient-safety-the-role-of-qr-code-implementation-in-pharma-labeling
16. Kresankova K. 8 trends shaping the future of drug labeling. Schlafender Hase [Internet]. 2025 Jan 12 [cited 2025 Sep 14]. Available from: https://www.schlafenderhase.com/insights/8-trends-drug-labeling
17. Vredenburgh AG, Zackowitz IB. Drug labeling and its impact on patient safety [Internet]. Work. 2009;33(2):169–74 [cited 2025 Sep 14]. Available from: https://www.researchgate.net/publication/26773524_Drug_labeling_and_its_impact_on_patient_safety
18. Parate N. Harmonizing labeling for multiple product variants: ensuring safety and compliance [Internet]. Freyr Solutions. 2023;16(3):78–83 [cited 2025 Sep 14]. Available from: https://www.freyrsolutions.com/blog/harmonizing-labeling-for-multiple-product-variants-ensuring-safety-and-compliance